EP1061908A4 - Kombinationstherapie und zusammenstellung für akutes koronarischämiesyndrom und damit zusammenhängende zustände - Google Patents

Kombinationstherapie und zusammenstellung für akutes koronarischämiesyndrom und damit zusammenhängende zustände

Info

Publication number
EP1061908A4
EP1061908A4 EP99911208A EP99911208A EP1061908A4 EP 1061908 A4 EP1061908 A4 EP 1061908A4 EP 99911208 A EP99911208 A EP 99911208A EP 99911208 A EP99911208 A EP 99911208A EP 1061908 A4 EP1061908 A4 EP 1061908A4
Authority
EP
European Patent Office
Prior art keywords
composition
combination therapy
related conditions
acute coronary
ischemic syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99911208A
Other languages
English (en)
French (fr)
Other versions
EP1061908A1 (de
Inventor
Steven A Nichtberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815857.9A external-priority patent/GB9815857D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1061908A1 publication Critical patent/EP1061908A1/de
Publication of EP1061908A4 publication Critical patent/EP1061908A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
EP99911208A 1998-03-13 1999-03-09 Kombinationstherapie und zusammenstellung für akutes koronarischämiesyndrom und damit zusammenhängende zustände Withdrawn EP1061908A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7790098P 1998-03-13 1998-03-13
US77900P 1998-03-13
GBGB9815857.9A GB9815857D0 (en) 1998-07-21 1998-07-21 Combination therapy for treating preventing or reducing the risks associated with acute coronary ischemic syndrome and related conditions
GB9815857 1998-07-21
PCT/US1999/005063 WO1999045913A1 (en) 1998-03-13 1999-03-09 Combination therapy and composition for acute coronary ischemic syndrome and related conditions

Publications (2)

Publication Number Publication Date
EP1061908A1 EP1061908A1 (de) 2000-12-27
EP1061908A4 true EP1061908A4 (de) 2007-01-24

Family

ID=26314085

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99911208A Withdrawn EP1061908A4 (de) 1998-03-13 1999-03-09 Kombinationstherapie und zusammenstellung für akutes koronarischämiesyndrom und damit zusammenhängende zustände

Country Status (4)

Country Link
EP (1) EP1061908A4 (de)
JP (1) JP2002506024A (de)
CA (1) CA2322824A1 (de)
WO (1) WO1999045913A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
EA200100966A1 (ru) * 1999-03-11 2002-02-28 Дюпон Фармасьютикалз Компани ЛЕЧЕНИЕ ТРОМБОЗА КОМБИНИРОВАННЫМ ПРИМЕНЕНИЕМ ИНГИБИТОРА ФАКТОРА Xa И АСПИРИНА, АКТИВАТОРА ТКАНЕВОГО ПЛАЗМИНОГЕНА (TPA), АНТАГОНИСТА GPIIB/IIIA, НИЗКОМОЛЕКУЛЯРНОГО ГЕПАРИНА ИЛИ ГЕПАРИНА
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
ES2364155T3 (es) * 2002-11-25 2011-08-25 Jallal Messadek Composiciones de betaína y ácido acetilsalicílico.
JP2004189711A (ja) * 2002-12-11 2004-07-08 Raul Altman 急性冠動脈症候群および関連病態の治療のための抗血小板薬と組合せたメロキシカムの使用
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
MX2007013486A (es) 2005-04-27 2008-03-14 Jallal Messadek Combinaciones de insulinas.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105988A (en) * 1981-09-18 1983-04-07 Rocador Sa Anti-platelet aggregation dipyridamole with Al aspirin
WO1997021445A1 (en) * 1995-12-12 1997-06-19 Omeros Medical Systems, Inc. Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO1997029753A1 (fr) * 1996-02-19 1997-08-21 Sanofi Nouvelles associations de principes actifs contenant du clopidogrel et un antithrombotique
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
WO1997044027A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997045420A1 (en) * 1996-05-31 1997-12-04 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
WO1998000416A1 (en) * 1996-07-03 1998-01-08 Merck & Co., Inc. Process of preparing phenyl heterocycles useful as cox-2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
UA57002C2 (uk) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
AU2202397A (en) * 1996-03-28 1997-10-17 G.D. Searle & Co. Iib/iiia antagonists co-administered with aspirin and/or heparin
HU224315B1 (hu) * 1996-06-05 2005-07-28 Gyógyszerkutató Intézet Kft. Véralvadásgátló hatású peptidil-arginin-aldehid-származékok és a vegyületeket tartalmazó gyógyszerkészítmények
AU723179B2 (en) * 1996-07-18 2000-08-17 Merck Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105988A (en) * 1981-09-18 1983-04-07 Rocador Sa Anti-platelet aggregation dipyridamole with Al aspirin
WO1997021445A1 (en) * 1995-12-12 1997-06-19 Omeros Medical Systems, Inc. Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO1997029753A1 (fr) * 1996-02-19 1997-08-21 Sanofi Nouvelles associations de principes actifs contenant du clopidogrel et un antithrombotique
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
WO1997044027A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997045420A1 (en) * 1996-05-31 1997-12-04 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
WO1998000416A1 (en) * 1996-07-03 1998-01-08 Merck & Co., Inc. Process of preparing phenyl heterocycles useful as cox-2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9945913A1 *

Also Published As

Publication number Publication date
WO1999045913A1 (en) 1999-09-16
EP1061908A1 (de) 2000-12-27
JP2002506024A (ja) 2002-02-26
CA2322824A1 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
IL126546A (en) Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin
GB2291053B (en) Inorganic composition
HUP0101804A3 (en) Adjuvant composition and methods for its use
IL122447A0 (en) Pharmaceutical composition with anaestheric effect
CY2506B1 (en) Composition
HUP0203746A3 (en) Novel composition and method for stabilizing the same
GB9813271D0 (en) Composition and use
PL347357A1 (en) Novel composition and use
EP1061908A4 (de) Kombinationstherapie und zusammenstellung für akutes koronarischämiesyndrom und damit zusammenhängende zustände
ZA975902B (en) Topical composition
PL342600A1 (en) Composition
ZA976791B (en) Composition comprising mupirocin and chlohexidine
EP0884044A4 (de) Haarbehandlungsmittel
GB9806788D0 (en) Composition
GB9600604D0 (en) Composition
GB9827894D0 (en) Composition
GB9806793D0 (en) Composition
ZA972756B (en) Topical composition
GB9814869D0 (en) Process and composition
GB9606579D0 (en) Pharmaceutical composition and methods for the manufacture thereof
GB9914796D0 (en) Composition
GB9903310D0 (en) Composition
GB9804041D0 (en) Composition
HUP0101602A3 (en) Fertility improving composition and application thereof
GB9815857D0 (en) Combination therapy for treating preventing or reducing the risks associated with acute coronary ischemic syndrome and related conditions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001013;LT PAYMENT 20001013;LV PAYMENT 20001013;MK PAYMENT 20001013;RO PAYMENT 20001013;SI PAYMENT 20001013

A4 Supplementary search report drawn up and despatched

Effective date: 20061227

17Q First examination report despatched

Effective date: 20070810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080221